© 2022 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
With less than a week to go until the close of 2022, our editorial team is celebrating the final week of the year by recapping some of our most popular stories and content from the past year. Here, we are highlighting our most popular content related to new guidelines and recommendations related to diabetes management from 2022. Our recap includes the 2023 Standards of Care, USPSTF recommendation on type 2 diabetes screenings in adolescents, recommendations for pharmacologic management of obesity, new bariatric surgery guidance, and a consensus report on use of automated insulin delivery.
The American Diabetes Association has released their updated Standards of Care for 2023 with the goal of providing the diabetes care team within an overview of diabetes management, including updates in diabetes technology, obesity, hypertension, heart failure medication, and lipid management.
The 2023 version of the living document, which has been updated annually since 1989, contains more than 100 updated recommendations within its 17 sections, with new updates highlighting the latest advances in clinical aspects of diabetes management, such as pharmacologic approaches to glycemic treatment, but also related to holistic diabetes management, including patient-first language and the influence of social determinants of health.
The US Preventive Services Task Force has released their first recommendation statement outlining the organization’s stance on screening for prediabetes and type 2 diabetes in children and adolescents without known diabetes or prediabetes or without symptoms of either.
Released on September 13, the USPSTF concluded in their recommendation statement, which is the first on the subject for this particular patient population, that there was insufficient evidence to assess the balance of benefits and harms of screening for type 2 diabetes or prediabetes in children and adolescents, awarding an I grade to the statement.
The American Gastroenterological Association has released new guidance outlining the organization’s stance on evidence-based approaches to management of obesity using pharmacological interventions.
Released on October 20, the document, which was composed by a multidisciplinary panel of content experts and guideline methodologists using the GRADE framework, endorses multiple semaglutide 2.4 mg (Wegovy), phentermine-topiramate ER (Qsymia), liraglutide 3 mg (Saxenda), and naltrexone-bupropion ER (Contrave) as first-line medical therapies in addition to diet and exercise for weight loss in people with obesity.
After a more than 30-year wait, bariatric and metabolic surgeons have a new set of international, evidence-based guideline recommendations for weight loss surgery.
Published on October 21 by the American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), the guideline recommendations were created with the intent of replacing those developed for the 1991 consensus statement from the National Institutes of Health and include multiple changes, including expanding the patient population for metabolic and bariatric surgery to include patients with type 2 diabetes and a BMI of 30 kg/m2 or greater.
The American Diabetes Association and the European Association for the Study of Diabetes have released a new consensus report aimed at providing evidence-based recommendations as well as an overview of the benefits and challenges with automated insulin delivery.
Published on October 6, the document reflects the rapid advancement of AID technology in recent years and was composed by a joint Diabetes Technology Working Group, the same group that wrote the organizations' first consensus report on insulin pumps in 2015.
Related Content: